Novalis LifeSciences
VC Fund
Hampton, United States
Novalis LifeSciences is a VC fund in Hampton focused on Biotechnology and Health Care. Novalis Lifesciences LLC, is a globally acting venture capital firm focused on breakthrough technologies in Life Science. Founded and managed by Dr. Marijn E. Dekkers, current chairman of Unilever and former chief executive officer of Bayer AG and Thermo Fisher Scientific Inc., Novalis works with a diversified group of project-based specialistsleading in their respective life science fields
- Total investments:
- 25
- Last investment:
- Lead investor:
- 64%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Novalis LifeSciences invests in
Stages Novalis LifeSciences invests in
Countries Novalis LifeSciences invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Marijn Dekkers
|
|||
Paul Meister
|
|||
Investment Focus
Industry
- Biotechnology 14 (56%)
- Health Care 8 (32%)
- Therapeutics 6 (24%)
- Agriculture 3 (12%)
- Health Diagnostics 3 (12%)
Stage
- Series B 7 (28%)
- Series C 5 (20%)
- Series D 3 (12%)
- Seed 2 (8%)
- Post-IPO Equity 2 (8%)
Country
- United States 13 (52%)
- Belgium 2 (8%)
- United Kingdom 1 (4%)
- The Netherlands 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Marijn Dekkers
Chairman/Founder
|
Chairman/Founder | Total investments: 12 | Find email | |
|
Paul Meister
Executive
|
Executive | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Flywheel.io
|
Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from topuniversities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT.Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT. | $27.5M / Dec 23, 2025 | |
Animol Discovery
|
Animol is building its own pipeline of break-through proprietary veterinary small molecules led by a team of animal health industry experts with vast experience in bringing drugs to market. With our unique and powerful technology platform we deliver innovative medicines that are specifically designed for the needs of veterinary patients. | $12M / Series C / Oct 17, 2025 | |
Mercy BioAnalytics
|
Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.It has developed a process that uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer.Paul Blavin and Joseph Sedlak founded the Natick, Massachusetts-based company in 2018. | $59M / Series B / Sep 03, 2025 | |
BlueWhale Bio
|
BlueWhale Bio is spinout from the University of Pennsylvania to accelerate the use of cell-based therapies by manufacturing innovation. | $18M / Seed / Sep 07, 2023 | |
|
Flywheel.io
|
Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from topuniversities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT.Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT. | $54M / Series D / Jun 03, 2023 | |
Telesis Bio
|
Telesis Bio is a biotech company that empowers researchers with the tools to secure design, code, and create synthetic DNA and mRNA. Telesis Bio was founded in 2013 and was headquartered in San Diego, USA. | $74.2M / Post-IPO Equity / May 31, 2023 | |
|
Animol Discovery
|
Animol is building its own pipeline of break-through proprietary veterinary small molecules led by a team of animal health industry experts with vast experience in bringing drugs to market. With our unique and powerful technology platform we deliver innovative medicines that are specifically designed for the needs of veterinary patients. | $9.2M / Series B / Apr 17, 2023 | |
|
Mercy BioAnalytics
|
Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.It has developed a process that uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer.Paul Blavin and Joseph Sedlak founded the Natick, Massachusetts-based company in 2018. | $41M / Series A / Apr 03, 2023 | |
LevitasBio
|
Levitas, Inc. is redefining cellular analytics with its novel platform magnetic levitation technology. Their disruptive technology overcomes the current technological limitation of cellular analysis by providing label-free, simple, and universal methods of analysis. The company's platform, the LeviCell enables studies and beneficial uses ofpreviously inaccessible, high-value primary samples, and sensitive cell types regardless of the starting cell number, viability, or sensitivity to processing. | $35M / Series C / Oct 24, 2022 | |
etherna immunotherapies
|
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable andsafer enhancement of the patient’s immune system than any other similar approach investigated until now. | $38.9M / Series B / Aug 23, 2022 | |
| See all 25 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Novalis LifeSciences invest in?
Novalis LifeSciences invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Novalis LifeSciences?
Public channels for Novalis LifeSciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Novalis LifeSciences?
The team at Novalis LifeSciences includes Marijn Dekkers (Chairman/Founder) and Paul Meister (Executive). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
